Our Guardant Reveal #liquidbiopsy test was approved by the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for the detection and monitoring of minimal residual disease #MRD in patients with early-stage cancer. bit.ly/3wdczfP
1
8
77
Breaking news: Guardant360 CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling in patients with any solid cancer. This is a landmark decision, demonstrating the value #liquidbiopsy delivers to oncologists and patients. bit.ly/33CN2kk
1
50
85
Join experts @drgandara, Natasha Leighl, and @MDuruisseaux as they share the latest #liquidbiopsy advancements for #cancer and the value of the Guardant360 tests to support treatment decisions at the Annual @isliquidbiopsy Congress.
Register here: bit.ly/30i9nnF
ALT Guardant Health Symposium | 2021 ISLB Congress | October 22, 2021 15:00 CEST
1
12
65
We’re changing the game for #ColorectalCancer screening w/ the FDA approval of Shield, our blood test for people age 45+ at average risk. With Shield, we aim to get more people tested & catch more cancers early, when they’re most treatable.
Read more: bit.ly/3WnfKzi
2
52
42
11,760
We’re proud to announce that Shield, our highly sensitive blood test to detect early signs of #colorectalcancer, is now available in the U.S. for adults 45 and up who are not up to date with current #screening guidelines and at average risk for #CRC. bit.ly/3OV5tGe
15
20
34
We're excited to announce our partnership with @VHIO to establish the first Guardant Health #liquidbiopsy testing service in Europe, for clinical research and clinical patient care, at VHIO’s facility in Barcelona. bit.ly/3bUv6pl
10
32
Learn how Guardant Health's liquid biopsies can help conquer cancer with data. Read this great @WiredUK piece: bit.ly/2lhaqLD
20
26
We proudly announce two new tests for patients with advanced cancer. Our Guardant360 Response test for treatment response monitoring and our Guardant360 TissueNext test if needed for efficient "blood-first, tissue-next" complete genomic testing. Read more: bit.ly/35MCgb3
5
15
23
We’re excited to announce the COBRA study with @NRGOnc to validate the clinical utility of our molecular residual disease assay as a diagnostic biomarker for selecting which patients with stage II colon cancer need adjuvant chemotherapy.
investors.guardanthealth.com…
15
27
We're pleased to announce our Guardant360 CDx test has received FDA approval as the first and only companion diagnostic for @JanssenUS's approved targeted treatment for use in patients with advanced non-small cell #lungcancer harboring certain mutations. bit.ly/3fyMws0
7
25
We're pleased to welcome Craig Eagle, MD as our Chief Medical Officer. Dr. Eagle is a respected leader in oncology, with extensive experience driving medical affairs, clinical development, and clinical trial operations at leading pharmaceutical companies.
bit.ly/33aG0Sm
4
6
21
At Guardant Health, our #CancerMoonshot dream for colorectal cancer is for all patients to have access to life-saving technologies, like blood-based screening, that can help identify cancers at their earliest stages. What’s your #MyCRCMoonshot dream? @FightCRC
6
26
We were honored to participate in @FightCRC’s Climb for a Cure event on Sunday. Our employees joined forces with the #colorectalcancer community to raise awareness and funding for #cancerresearch of CRC, the second leading cause of cancer death.
2
3
21
Read this timely article in @science2_0 by our CEO Helmy Eltoukhy on how real world evidence can help mitigate the calamitous effects COVID-19 has had on #cancerresearch, and change the oncology research landscape for the better. #RWE bit.ly/2SD4SRa
5
7
20
Only 18% of advanced #lungcancer patients get complete genomic testing before first-line treatment. We've teamed up with @LUNGevity @GO2Foundation @ALKLungCancer to help change this statistic. Learn about the #ClearYourView initiative: clearyourview.org/ #LCAM #LungAmbition
3
13
19
Read the new article in @RealClearHealth by Guardant Health CEO Helmy Eltoukhy. Helmy discusses the impact the #COVID19 shutdowns have had on delaying routine cancer screenings and the likelihood of a post-pandemic spike in advanced #cancer diagnoses: bit.ly/3tW0wkH
2
6
20
We’re honored to be featured in this important @TIME article on #liquidbiopsies, including our FDA-approved Guardant360 CDx test, and their potential to transform cancer care at all stages. bit.ly/3mIxId0
1
6
18
What an inspiring day! Today we hosted @TheWRP4LC at our headquarters to observe Lung Cancer Awareness Month. We were so privileged to be joined by people living with lung cancer who have become passionate advocates for lung cancer screening and treatment advances. #LCAM
1
6
19
Today we announced our Guardant360 CDx test received FDA approval as the first and only #liquidbiopsy companion diagnostic for @Amgen approved targeted treatment for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell #lungcancer. bit.ly/3vxSKPp
9
18
We applaud @POTUS for his SOTU commitment to end cancer as we know it & cut cancer deaths by 50%. Blood-based #colorectalcancer screening & detection will help achieve the #CancerMoonshot goals and we look forward to our continued work with @DCarnival46 & this Administration.
2
19
1,357
We are proud to initiate the ECLIPSE trial, a 10,000-patient, pivotal study for our LUNAR-2 blood test for colorectal cancer screening.
Read more: investors.guardanthealth.com…
5
17
We are on our way to closing the #ColorectalCancer screening gap with our Shield blood test. Results of our 20,000-patient ECLIPSE study are now published in @NEJM, reinforcing the validity of the test.
Read more: investors.guardanthealth.com…
7
16
2,087
We are honored to be recognized by @SFBusinessTimes and @svbizjournal for the second consecutive year on their Middle Market 75 list, ranking 5th for revenue growth and 9th overall amongst the fastest growing Bay Area companies.
bit.ly/35WLeCG
1
14
At #ASCO21, we present data showing that our LUNAR-2 blood test is a highly sensitive test that can detect #CRC in early-stage cancer patients. This largest ever cohort continues to demonstrate the performance of the LUNAR-2 #liquidbiopsy. bit.ly/3fQxDCp
6
18
We're excited to announce our partnership with @royalmarsdenNHS to establish the first Guardant Health #liquidbiopsy testing service based in the United Kingdom for clinical research and clinical patient care.
bit.ly/3BKUbfA
10
17
Lung cancer is the leading cause of cancer death. On #WorldLungCancerDay, we’re proud to join forces with
@GO2Foundation @LUNGevity @ALKLungCancer to raise awareness of the importance of complete biomarker testing for lung cancer patients like Patty. clearyourview.org
14
17
It's an honor to win a @MedTech_Awards Breakthrough Award 2021 for Best Personal Genomic Testing Service. Our recognized Guardant360 CDx #liquidbiopsy enables faster, complete genomic testing to help patients with advanced cancer find the best treatment. bit.ly/3tm0ceO
3
14
In partnership with @VHIO, we're excited to announce the first blood-based #cancer testing services in Europe based on our digital sequencing platform are now available in Barcelona. This service will support patient access to our #liquidbiopsy technology.
bit.ly/3yYL1yA
6
17
To help accelerate #precisiononcology drug development, we're proud to unveil the GuardantINFORM platform, featuring an extensive real-world, clinical-genomic #liquidbiopsy dataset of advanced cancer patients. bit.ly/2CzDUkY
9
17
The #USPSTF has updated their guidelines, lowering the #colorectalcancer screening age to 45 for people at average risk. We applaud the USPSTF and are hopeful that, along with efforts to achieve compliance, this can increase early detection and treatment. bit.ly/2ScDJnh
7
13
Our Shield blood test is now covered by #Medicare and is commercially available in the U.S. as the first FDA-approved blood test for primary #ColorectalCancer screening.
4
14
1,082
Today we're excited to announce a strategic collaboration with @Radius_Health to develop Guardant360 CDx as a companion diagnostic for elacestrant, a selective estrogen receptor degrader in phase III trial for use in resistant ER-positive #breastcancer. bit.ly/3hPwbyu
12
15
This Wednesday at Liquid Biopsy for #PrecisionOncology Summit, join Guardant Health's VP of Outcomes and Evidence Kathryn Lang and Director of BD Patrick Eimerman for a discussion on Opportunities for #LiquidBiopsy Across the Continuum of Care. bit.ly/3tGh15j
6
16
Today we’re celebrating an important milestone in our goal to help transform cancer care at all stages of the disease. We’ve delivered more than 500,000 test results to support patients and healthcare providers in cancer care decisions. #precisionmedicine #cancerdiagnostics
8
14
882
Early #cancerdetection saves lives. Yet too many patients are not getting the screenings they need. Join us for an @AspenIdeas #AspenIdeasHealth chat on 11/10 with @FightCRC and @DrJohnTorres to explore how new technologies can help close this care gap.
bit.ly/AIHCancerScreening
9
16
We’re thrilled to receive U.S. FDA approval for our Guardant360 CDx liquid biopsy test as a companion diagnostic to identify advanced #breastcancer patients with ESR1 mutations who may benefit from @Stemline's ORSERDU targeted therapy.
bit.ly/3DqK43h
5
16
1,344
2.1 million people are diagnosed w/ #lungcancer each year globally. Yesterday, we joined @AstraZeneca, @IASLC and @globalungcancer to announce the #LungAmbition Alliance, to one day end the disease as a cause of death: lungambitionalliance.org/
#lcsm
4
15
Together with @CCAlliance @FightCRC @GlobalCRC @kRasKickers @paltown1 we're proud to support the #ClearYourView initiative to raise awareness of the importance of complete biomarker testing for all advanced #colorectalcancer patients. #CRCAwarenessMonth clearyourview.org
2
8
14
Two years ago, Star was diagnosed with stage IV #lungcancer. A #liquidbiopsy test helped her get on the right targeted therapy. Learn about the #ClearYourView initiative and importance of complete #genomictesting for all advanced #NSCLC patients: clearyourview.org #LCAM
6
14
It’s been 10 years since Guardant Health was founded! Our co-founders Helmy Eltoukhy, AmirAli Talasaz and Michael Wiley gathered with employees this week at our new headquarters in Palo Alto to celebrate this milestone 🎉 #ConquerCancer
1
3
14
Today we announced a major upgrade to our market-leading Guardant360 test. It now covers 10x more genomic biomarkers, including all guideline-recommended ones across advanced solid tumors, and quantifies tumor burden with 10x higher sensitivity.
Details: bit.ly/3Yc68d9
4
14
867
Today we announced exciting updates for 2021 bringing us closer to our vision of transforming cancer care across the continuum. See our complete presentation from the @jpmorgan 39th Annual Healthcare Conference. bit.ly/3i4Qd9J
11
15
Congratulations to our cofounders @Helmy_L2K and AmirAli Talasaz for making @FortuneMagazines's 40 under 40 list! for.tn/2i915Yw
2
15
Did you know screening is the number one way to prevent colorectal cancer? Guardant Health's Screening Commercial team is showing their support for #ColorectalCancerAwarenessMonth by participating in @CCAlliance's #DressInBlueDay to raise awareness of CRC.
1
3
14
1,815
The potential to target KRAS G12C, a mutation that was once thought to be undruggable, represents a potentially major therapeutic advancement.
1
5
15
By ringing this morning's bell, we celebrate another pivotal moment in our journey to conquer cancer with data with the FDA approval of our Shield blood test.
#ThankYou to our dedicated team, partners, and supporters who have made this achievement possible!
3
13
1,646
We're humbled to be included in @FastCompany's World Changing Ideas 2021 for our next generation sequencing-based #COVID19 diagnostic test, which we rapidly developed to be additive to the limited testing options available. #FCWorldChangingIdeas bit.ly/33kHo4O
4
13
We're proud to announce that our Guardant360 CDx #liquidbiopsy test has received the #CEmark for comprehensive tumor mutation profiling across all solid cancers. bit.ly/2PsK1hq
7
12
We’re teaming up with @FightCRC to honor the contributions of #colorectalcancer researchers and advocates committed to getting people back to routine CRC #cancerscreening during the pandemic, including Principal Investigators of our ECLIPSE clinical trial.
bit.ly/2USFRC9
4
13
We’re delighted to be recognized as one of North America's fastest growing technology companies on @DeloitteTMT's 2020 Technology #Fast500 list. Thank you to our dedicated teams and partners and congratulations to all the winners! bit.ly/38XoIfA
7
14
By 2030, #ColorectalCancer is projected to be the No. 1 cancer killer for those under 50. We are excited to join @FightCRC, advocates and partners on the National Mall tomorrow to fight for more. Watch the livestream March 16 at 9:45am ET: fightcolorectalcancer.org/co…
6
12
Oncologists who performed liquid biopsy in patients with #NSCLC found more biomarkers than w/ tissue biopsy alone and received liquid results faster, according to a study in @ClinicalLung. Outcomes were similar regardless of biopsy used to guide treatment.
bit.ly/3HpwqAy
7
13
Bravo @CCAlliance and @LeadFromBehind! Raising awareness about the importance of screening for #colorectalcancer is so important and can save lives. #crc
WOW.
10 MILLION views of Ryan & Rob's video in just a day.
You've blown our behinds away.
Thank you.
#LeadFromBehind
4
12
Come visit the @GuardantHealth booth #4096 at the @ASCO Annual Meeting where we’ll share the latest advancements in #precisiononcology along with critical insights from real-world #oncology data. We look forward to seeing you there.
3
14
We're committed to helping #colorectalcancer patients at all stages live longer, healthier lives. This #ColorectalCancerAwarenessMonth we celebrate the progress that's been made and strive toward continued advancements in testing and screening. #CRC #liquidbiopsy
7
13
This tweet is unavailable
No one expects to get #lungcancer, especially when you have no ‘risk factors.’ Like Christina, living w/ #ALKPositive #lungcancer since 2019.
@ChristinaHers10 advocates for research, for more survival & more hope. Please help alkpositive.kindful.com/.
#MoreResearchMoreLife #LCAM
In Ohio and Pennsylvania, only 68% and 70% of eligible adults are screened for #colorectalcancer respectively. With @FightCRC, we honor Dr. Friedenberg of OH & Dr. Surace of PA for their commitment to #cancerscreening and patient enrollment into the ECLIPSE clinical trial.
3
11
We are partnering with The Royal Marsden NHS Foundation Trust on our TRACC Part C trial to use our Guardant Reveal blood test to help guide treatment decisions in colorectal cancer. Trial will involve approx. 40 sites across the U.K. More: bit.ly/3HiQyUw @royalmarsdenNHS
5
14
2,139
We’re proud to stand alongside our incredible advocacy partner groups, who are driving real change in the fight against lung cancer — this #LungCancerAwarenessMonth and every month.
@GO2forLungCancr, @LungAssociation, @LUNGevity, @LungPolicy, @LungAmbition, @LungCAN, @ALKPositiveinc, @IASLC, @Exon20Group, @WarOnCancer, and @KRASKickers.
Their dedication is making a difference in the lives of countless individuals and families, and we are honored to be part of this movement. We invite you to join us in supporting the vital work of these organizations. Together, we can make strides toward a world where no one faces #LungCancer alone.
1
1
13
678
Yesterday, we celebrated the opening of our new facility in San Diego. We are thrilled to expand our operations to support the development of #oncology therapeutics and next generation #bloodtests to help patients with #cancer live longer and healthier lives.
2
13
Today, @POTUS will convene representatives, including @GuardantHealth's Co-CEO @Helmy_L2K, to discuss the #CancerMoonshot and reducing the impact of #cancer. We look forward to working together to ensure patients have access to innovations in #cancercare. bit.ly/3wbV3ZW
1
14
Proud to announce a broad effort to detect cancer earlier. Our #CancerMoonshot bit.ly/projectlunar
1
7
12
A new study in JCO Precision Oncology adds to the growing body of evidence demonstrating that a blood-first approach using Guardant360 #liquidbiopsy can identify more actionable biomarkers with similar treatment response rate and progression-free survival. bit.ly/2MwdAwU
7
11
This tweet is unavailable
Evan was diagnosed with #ColorectalCancer when he was just 24 years old. By 2030, CRC is estimated to be the leading cause of cancer deaths for 20-49 year olds. We need to know why! #PrioritizeCRC research @POTUS and @VP! FightCRC.org/DayofAction
We've entered into a collaboration with AstraZeneca to develop our Guardant360 CDx blood test as a companion diagnostic to identify patients with ESR1-mutated metastatic breast cancer. See press release: bit.ly/3iQjfhP
4
11
We look forward to presenting data highlighting advances in #precisiononcology, including new research on the value of our GuardantINFINITY platform, at @AACR's Annual Meeting April 14-19. Learn more: bit.ly/3GBWgzP
3
7
823
We are pleased to announce that we have submitted the final module of our pre-market approval application to the U.S. FDA for Shield, our blood test to screen for colorectal cancer. bit.ly/3LdOOhC
4
11
943
Great to see this acknowledgement in @GenomeWeb of the potential for Guardant Galaxy, our suite of advanced AI analytics to enhance our test performance, starting with AI-backed image analysis developed by @Lunit_AI to improve PD-L1 #biomarker detection in patients with NSCLC.
Digital Pathology Offers New Diagnostics Frontier for Leading Cancer Sequencing Firms. Companies that built their business in tissue and blood-based DNA analyses are now exploring imaging technologies across a variety of fronts. ow.ly/krfm104AVAP
3
11
808
A new study published in @NatureMedicine and led by the NCCHE in Japan demonstrates that Guardant360 #liquidbiopsy accelerates clinical trial enrollment compared to tissue biopsy in patients with advanced #gastrointestinal cancer. bit.ly/3d3Wf7H
6
12
Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy
bit.ly/2mEX8hh
2
12
This is an important new development for Medicare patients with advanced cancer and for Guardant Health.
Medicare will expand coverage for Guardant360 across the vast majority of solid tumor cancers.
Read more: investors.guardanthealth.com…
1
5
11
“Biomarker companies, like Guardant Health, helped me to find the right treatment which has extended my life — by 7 years and counting.” Read @ajpatel_ca's inspiring story of surviving Stage IV #lungcancer with #precisionmedicine in @AuthorityMgzine.
bit.ly/3k9hZEI
2
11
We're attending the Cancer Moonshot #ColorectalCancer Forum at the White House today! Convening key stakeholders can bring us one step closer to achieving @POTUS #CancerMoonshot goals and end #cancer as we know it. Livestream the event here: piped.video/watch?v=9NBkN3Su…
3
12
634
Next week, several of our leaders will be presenting at the Next Generation Dx Summit in Washington, DC. They'll discuss transforming cancer detection with liquid biopsy, medical policy, and trends in diagnostic regulation. bit.ly/3w11VdJ #NGDx22
6
12
Important new research from @UChicagoMed about the genomic heterogeneity of gastroesophageal adenocarcinoma. prn.to/2jsMHM1
4
10
"This November let’s make sure no advanced #lungcancer patients are left behind and that they receive the testing and personalized care they deserve." Our CEO Helmy Eltoukhy shares with @RealClearHealth why complete genomic testing is so important. #LCAM bit.ly/3n7aGM4
7
12
This tweet is unavailable
More and more young adults are being diagnosed with #ColorectalCancer and we don’t know why. We need answers. We need more research. @POTUS and @VP will you work with us to #PrioritizeCRC?
FightCRC.org/DayofAction
